Pipeline

Insmed is developing and investigating treatments for rare lung diseases. Current product candidates utilize proprietary technology designed specifically for delivery of pharmaceuticals to the lung.

Product Pipeline

Preclinical Phase 1 Phase 2 Phase 3 Commercial
Amikacin Liposome Inhalation Suspension
(pulmonary nontuberculous mycobacteria)
Amikacin Liposome Inhalation Suspension
(Pseudomonas aeruginosa in cystic fibrosis)
INS1007
(non-cystic fibrosis bronchiectasis)
INS1009
(pulmonary arterial hypertension)
Additional proprietary programs